Current state and perspectives of CAR T cell therapy in central nervous system diseases
Brain · 06.03.2025 · 148 (3) · 723-736
DOI: 10.1093/brain/awae362 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain, online erschienen am 12.11.2024. Verfasst von Lena Kristina Pfeffer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Central Nervous System Diseases, T-Lymphocytes, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 161 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft, Walter and Ilse Rose Stiftung.
Abstract (Originalsprache)
B cell-directed CAR T cell therapy has fundamentally changed the treatment of haematological malignancies, and its scope of application is rapidly expanding to include other diseases such as solid tumours or autoimmune disorders. Therapy-refractoriness remains an important challenge in various inflammatory and non-inflammatory disorders of the CNS. The reasons for therapy failure are diverse and include the limited access current therapies have to the CNS, as well as enormous inter- and intra-individual disease heterogeneity. The tissue-penetrating properties of CAR T cells make them a promising option for overcoming this problem and tackling pathologies directly within the CNS. First application of B cell-directed CAR T cells in neuromyelitis optica spectrum disorder and multiple sclerosis patients has recently revealed promising outcomes, expanding the potential of CAR T cell therapy to encompass CNS diseases. Additionally, the optimization of CAR T cells for the therapy of gliomas is a growing field. As a further prospect, preclinical data reveal the potential benefits of CAR T cell therapy in the treatment of primary neurodegenerative diseases such as Alzheimer’s disease. Considering the biotechnological optimizations in the field of T cell engineering, such as extension to target different antigens or variation of the modified T cell subtype, new and promising fields of CAR T cell application are rapidly opening up. These innovations offer the potential to address the complex pathophysiological properties of CNS diseases. To use CAR T cell therapy optimally to treat CNS diseases in the future while minimizing therapy risks, further mechanistic research and prospective controlled trials are needed to assess seriously the disease and patient-specific risk-benefit ratio.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
- Department of Neurology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
ORCID-Profile: Lena Kristina Pfeffer, Felix Fischbach, Christoph Heesen, Manuel A Friese
Förderung
- Deutsche Forschungsgemeinschaft
- Walter and Ilse Rose Stiftung
Zitieren
APA
Pfeffer, L. K., Fischbach, F., Heesen, C., & Friese, M. A. (2025). Current state and perspectives of CAR T cell therapy in central nervous system diseases. Brain, 148(3), 723-736. https://doi.org/10.1093/brain/awae362
Vancouver
Pfeffer LK, Fischbach F, Heesen C, Friese MA. Current state and perspectives of CAR T cell therapy in central nervous system diseases. Brain. 2025;148(3):723-736. doi:10.1093/brain/awae362
BibTeX
@article{Pfeffer2025,
author = {Pfeffer, Lena Kristina and Fischbach, Felix and Heesen, Christoph and Friese, Manuel A},
title = {Current state and perspectives of CAR T cell therapy in central nervous system diseases},
journal = {Brain},
year = {2025},
volume = {148},
number = {3},
pages = {723--736},
doi = {10.1093/brain/awae362}
}
EUVIMED